EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Pancreatic islet cell tumors


Surgery 99(6): 671-678
Pancreatic islet cell tumors
Tumors arising from the pancreatic islet cells represent a heterogeneous group of lesions. Some tumors present with well-characterized syndromes, while others appear to be nonfunctioning. Eighty-four patients with pancreatic islet cell tumors operated on at the Cleveland [Ohio, USA]Clinic during a 35-year period were reviewed. The tumor types include 21 nonfunctioning tumors, 41 insulinomas, 16 gastrinomas, two vasoactive intestinal polypeptide (VIP)-omas, two carcinoids, and two probable cases of pancreatic parathyrinoma. Eleven patients had multiple endocrine neoplasia type I syndrome. Preoperative localization was possible in 63% of patients in whom it was attempted. Complete mobilization of the head and distal pancreas with bimanual palpation of the entire gland is critical for intraoperative tumor localization. Distal pancreatectomy is favored for tumors in the body and tail. In the head of the pancreas, small, benign lesions require enucleation, and large or malignant lesions necessitate a Whipple procedure. The operative morbidity rate was 24%, and the mortality rate was 3.6%. The 10-year survival rate was 54.7% for nonfunctioning lesions, 68.4% for gastrinomas, and 92.4% for insulinomas. At this time surgery represents the only way to cure these lesions.

(PDF 0-2 workdays service: $29.90)

Accession: 006059289

PMID: 2424108



Related references

Pancreatic islet cell tumors and their syndromes. II. Zollinger-Ellison syndrome, glucagonoma syndrome, multiple endocrine adenomatosis and islet cell tumors not obviously provable. Schweizerische Medizinische Wochenschrift 108(50): 1997-2007, 1978

Immunohistochemical identification of human pancreatic islet cell tumors using anti islet cell monoclonal autoantibodies. Cancer Immunology Immunotherapy 18(SUPPL): S39, 1984

Neuropilin-2 is a novel neuroendocrine marker expressed in pancreatic islet cells and islet cell tumors. Laboratory Investigation 81(1): 202A, January, 2001

Immunocytochemical localization of prohormone convertase 1/3 and 2 in pancreatic islet cells and islet cell tumors. Pancreas 23(2): 172-176, 2001

GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function. Metabolism: Clinical and Experimental 62(1): 70-78, 2013

Non-islet origin of pancreatic islet cell tumors. Journal of Clinical Endocrinology and Metabolism 89(4): 1934-1938, 2004

Retrospective study of 60 pancreatic islet cell tumors using immuno peroxidase staining for pancreatic hormones. Laboratory Investigation 44(1): 46A-47A, 1981

Pancreatic islet cell tumors and renal tumors in the male rat following neutron exposure. Research and Development Technical Report. United States. Naval Radiological Defense Laboratory, San Francisco: 1-17, 1961

Cytologic features of pancreatic endocrine tumors islet cell tumors. Acta Cytologica 28(5): 645-646, 1984

Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1. Surgery (st Louis). 122(6): 1012-1020,., 1997